Key result
99mTc-labeled GP IIb/IIIa antagonists show greater thrombus uptake versus controls in canine models.
Why the study?
The biological properties and thrombus imaging potential of 99mTc-labeled cyclic glycoprotein IIb/IIIa receptor antagonists in arterial and venous thrombi were not fully characterized.
The 99mTc-labeled cyclic glycoprotein IIb/IIIa receptor antagonist [99mTcO(L1-V)]- shows promise as a rapid imaging agent for detecting arterial and venous thrombi in canine models.
No clinical role yet; hypothesis-generating for 99mTc-GP IIb/IIIa thrombus imaging in humans.
A series of 99mTc-labeled cyclic glycoprotein IIb/IIIa receptor antagonists, [99mTcO(L1-III)]-, [99mTcO-(L6-III)]-, [99mTcO(L1-V)]-, and [99mTcO(L6-V)]-, were evaluated in a canine arteriovenous (AV) shunt model for their potential use as thrombus imaging agents. The thrombus formed consists of a platelet-rich head and a fibrin-rich tail. All four agents were incorporated into the growing thrombus under both arterial (platelet-rich) and venous (platelet-poor) conditions. The rank order for uptake was [99mTcO(L1-V)]- > [99mTcO(L6-V)]- > [99mTcO(L6-III)]- > [99mTcO(L1-III)]- (arterial range, 5.8-0.47% id/g; venous range, 0.58-0.04% id/g). The uptakes of both [99mTcO(L6-III)]- and [99mTcO-(L1-III)]- under both arterial and venous conditions were not significantly greater than that of [99mTc]-albumin and [125I]fibrinogen. In contrast, the uptakes of both [99mTcO(L1-V)]- and [99mTcO(L6-V)]- were significantly greater than those of [99mTc]albumin and [125I]fibrinogen and comparable to that of [111In]platelets under both arterial and venous conditions. All four [99mTc]chelator-peptide conjugates are cleared faster than the controls with the clearance of the conjugates of peptide III faster than that of the conjugates of peptide V. The differences in incorporation are attributable to the effect of both the cyclic peptide and the chelator. The conjugate [99mTcO(L1-V)]- was also studied using a canine DVT (deep vein thrombosis) model. [99mTcO(L1-V)]- was actively incorporated into the growing thrombus with images clearly detectable within 15 min postinjection. At 2 h postinjection, thrombus/blood and thrombus/muscle ratios [region of interest (ROI)/background] were approximately 7/1 and 10/1, respectively. This clearly demonstrated that the conjugate [99mTcO(L1-V)]- has the potential for rapid diagnosis of thrombolic events occurring under both arterial and venous conditions.
No takes yet. Share an insight, caveat, or question.
Barrett et al. (1996) studied Thrombus imaging (canine models). 99mTc-labeled cyclic glycoprotein IIb/IIIa receptor antagonists vs. [99mTc]albumin, [125I]fibrinogen, and [111In]platelets was evaluated on Thrombus uptake. The 99mTc-labeled cyclic glycoprotein IIb/IIIa receptor antagonists [99mTcO(L1-V)]- and [99mTcO(L6-V)]- showed significantly greater thrombus uptake than albumin and fibrinogen controls in canine models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: